Literature DB >> 26211819

Sepsis and beta-blockade: a look into diastolic function.

Marinella Astuto1.   

Abstract

There is growing interest on the modulation of the overwhelming sympathetic response of septic patients. Beta-blockers appear promising in this respect and, although we are at early stage, one large trial and a smaller one have demonstrated major beneficial effects. The modulation of diastolic function and the optimization of myocardial efficiency by beta-blockade is among the possible reason for the improvement in patients with severe sepsis or septic shock. It should be also considered that septic patients are at higher risk of cardiac arrhythmias and beta-blocker may have a protective effect in this regard. We are still at a preliminary stage and more research is needed it seems reasonable that beta-blockade will become an option for the treatment of septic patients over the next few years.

Entities:  

Keywords:  Beta blockade; Myocardial dysfunction; Septic shock; Severe sepsis

Mesh:

Substances:

Year:  2015        PMID: 26211819     DOI: 10.1185/03007995.2015.1073147

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Detecting impaired myocardial relaxation in sepsis with a novel tissue Doppler parameter (septal e'/s').

Authors:  David J Clancy; Michel Slama; Stephen Huang; Timothy Scully; Anthony S McLean; Sam R Orde
Journal:  Crit Care       Date:  2017-07-14       Impact factor: 9.097

2.  Application of updated guidelines on diastolic dysfunction in patients with severe sepsis and septic shock.

Authors:  David J Clancy; Timothy Scully; Michel Slama; Stephen Huang; Anthony S McLean; Sam R Orde
Journal:  Ann Intensive Care       Date:  2017-12-19       Impact factor: 6.925

3.  Factors associated with left ventricular diastolic dysfunction in patients with septic shock.

Authors:  Wei-Dong Ge; Feng-Zhi Li; Bang-Chuan Hu; Li-Hong Wang; Ding-Yuan Ren
Journal:  Eur J Med Res       Date:  2022-07-27       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.